NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 270 filers reported holding NOVOCURE LTD in Q1 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $3,024,769 | -40.6% | 72,886 | -13.9% | 0.14% | -47.1% |
Q1 2023 | $5,093,798 | +8.6% | 84,699 | +32.5% | 0.26% | -22.1% |
Q4 2022 | $4,690,072 | +12.6% | 63,941 | +16.6% | 0.33% | -1.8% |
Q3 2022 | $4,166,000 | -1.4% | 54,833 | -9.8% | 0.34% | -0.9% |
Q2 2022 | $4,226,000 | -1.1% | 60,802 | +17.9% | 0.34% | +59.9% |
Q1 2022 | $4,273,000 | +22.8% | 51,581 | +11.3% | 0.21% | +27.7% |
Q4 2021 | $3,480,000 | +159.3% | 46,344 | +301.2% | 0.17% | +39.5% |
Q3 2021 | $1,342,000 | -53.7% | 11,552 | -11.6% | 0.12% | -52.4% |
Q2 2021 | $2,900,000 | +105.1% | 13,075 | +22.2% | 0.25% | +85.2% |
Q1 2021 | $1,414,000 | -19.6% | 10,697 | +5.3% | 0.14% | -26.6% |
Q4 2020 | $1,758,000 | +62.6% | 10,157 | +4.6% | 0.18% | +38.3% |
Q3 2020 | $1,081,000 | +139.7% | 9,709 | +27.6% | 0.13% | +121.7% |
Q2 2020 | $451,000 | -2.8% | 7,608 | +10.4% | 0.06% | -28.6% |
Q1 2020 | $464,000 | -29.4% | 6,891 | -11.7% | 0.08% | -17.6% |
Q4 2019 | $657,000 | – | 7,800 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Invus Financial Advisors, LLC | 470,884 | $27,923,000 | 10.09% |
Darsana Capital Partners LP | 1,700,000 | $100,810,000 | 5.98% |
HARTLINE INVESTMENT CORP/ | 336,617 | $19,961,000 | 4.18% |
Rhenman & Partners Asset Management AB | 375,000 | $22,238,000 | 2.40% |
MORGAN JESS S & CO INC | 35,942 | $2,131,000 | 2.31% |
Soleus Capital Management, L.P. | 56,397 | $3,344,000 | 1.91% |
Bullseye Asset Management LLC | 45,161 | $2,678,000 | 1.43% |
Taylor Frigon Capital Management LLC | 46,304 | $2,746,000 | 1.36% |
COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $593,000 | 1.09% |
Redwood Investments, LLC | 192,986 | $11,444,000 | 1.01% |